Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to $89.6 million.

  • Lineage Cell Therapeutics' Liabilities and Shareholders Equity fell 720.02% to $89.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $405.4 million, marking a year-over-year decrease of 85.33%. This contributed to the annual value of $113.2 million for FY2024, which is 1207.59% up from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Liabilities and Shareholders Equity stood at $89.6 million, which was down 720.02% from $90.8 million recorded in Q2 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Liabilities and Shareholders Equity peaked at $174.5 million during Q4 2021, and registered a low of $89.6 million during Q3 2025.
  • Its 5-year average for Liabilities and Shareholders Equity is $118.4 million, with a median of $113.2 million in 2023.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Liabilities and Shareholders Equity soared by 6169.21% in 2021 and then crashed by 2915.06% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $174.5 million in 2021, then fell by 29.15% to $123.7 million in 2022, then fell by 18.31% to $101.0 million in 2023, then increased by 12.08% to $113.2 million in 2024, then fell by 20.83% to $89.6 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $89.6 million for Q3 2025, versus $90.8 million for Q2 2025 and $111.8 million for Q1 2025.